For research use only ยท Not for human or animal consumption
// Tissue & Cellular

LL-37 Research Guide

The 37-residue peptide that is the only human cathelicidin, sold as LL-37 5mg. Covers its structure, antimicrobial and immune signaling research, and skin wound models.

5Sources
3FAQs
4Min read
For research use only. Not for human consumption.
01

What is LL-37?

LL-37 is a 37-amino-acid, amphipathic, helical peptide and the only cathelicidin-derived antimicrobial peptide found in humans (Dรผrr et al., 2006). It is the C-terminal fragment of the precursor protein hCAP18, which is made constantly in white blood cells and induced in barrier tissues during inflammation and infection (Heilborn et al., 2003).

It is expressed in epithelial cells of the skin, gut, airways and testis, and in leukocytes such as monocytes, neutrophils, T cells, NK cells and B cells (Dรผrr et al., 2006). We supply it as LL-37 5mg.

02

Research areas studied

The findings below come from published cell, human tissue and animal research. They describe what studies have examined and reported, not effects of any research material.

Antimicrobial and immune activity

LL-37 shows a broad spectrum of antimicrobial activity in laboratory studies. Reported roles beyond killing microbes include regulating the inflammatory response, attracting cells of the adaptive immune system, and binding and neutralizing bacterial lipopolysaccharide (Dรผrr et al., 2006). A 2012 review also summarizes antifungal, antiviral, chemotactic, angiogenesis and apoptosis research, and notes a possible role in cancer (Vandamme et al., 2012).

Skin wound models

In human skin, hCAP18 levels rose after wounding, peaked at 48 hours and returned to baseline as the wound closed. In organ-cultured human skin, antibodies against LL-37 inhibited re-epithelialization in a concentration-dependent way, and hCAP18 was low in the edge epithelium of chronic ulcers (Heilborn et al., 2003).

Cell signaling and mouse studies

In the human keratinocyte line HaCaT, LL-37 increased cell migration through focal adhesion kinase and paxillin signaling, EGFR transactivation and the receptor FPRL-1. Adenoviral transfer of LL-37 to excisional wounds in ob/ob mice improved re-epithelialization and granulation tissue formation (Carretero et al., 2008).

Regulatory status and limits of the evidence

FDA’s compounding safety page lists cathelicidin LL-37 among nominated substances whose nominations were withdrawn, citing possible immunogenicity and limited safety information, and notes nonclinical findings of effects on male reproduction and tumor promotion in some tissues. Most of the research above concerns the body’s own peptide or gene transfer, not supplied research material.

03

Storage and handling

Like most research peptides, LL-37 is normally supplied for laboratory use as a lyophilized (freeze-dried) powder in a sealed vial. Check the label and the batch COA for the exact form of your lot. Zero Zero Collection recommends keeping vials refrigerated at 2 to 8 ยฐC and protected from light, as stated on every product page. Let a refrigerated vial reach room temperature before opening it so moisture does not condense on the powder.

When a lab reconstitutes lyophilized material, standard practice is to add a sterile diluent such as bacteriostatic water slowly down the inside wall of the vial, then swirl gently rather than shake. The volume depends on the concentration a protocol calls for, so follow your own lab’s validated method. Label the vial with the date, keep reconstituted material refrigerated, and follow your institution’s guidance on how long a solution stays usable.

04

Quality and documentation

We supply LL-37 as research material in a sealed, lot-traceable vial. Match the lot number on your vial to your order records, and contact our team at [email protected] with any lot-specific questions.

05

LL-37 FAQ

Why is it called LL-37?

The name comes from its first two amino acids, two leucines (LL), and its length of 37 residues.

Where does LL-37 come from in the body?

It is cut from the precursor protein hCAP18, which white blood cells make constantly and barrier tissues such as skin produce during inflammation and infection.

Is LL-37 an approved drug?

No. FDA lists cathelicidin LL-37 among bulk substances whose compounding nominations were withdrawn.

07

References

  1. Dรผrr UH, Sudheendra US, Ramamoorthy A (2006). Biochim Biophys Acta. PubMed 16716248
  2. Vandamme D, Landuyt B, Luyten W, et al. (2012). Cell Immunol. PubMed 23246832
  3. Heilborn JD, Nilsson MF, Kratz G, et al. (2003). J Invest Dermatol. PubMed 12603850
  4. Carretero M, Escรกmez MJ, Garcรญa M, et al. (2008). J Invest Dermatol. PubMed 17805349
  5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 28, 2026. fda.gov

For research use only. Not for human consumption. This guide summarizes published scientific literature for laboratory research context. It is not medical advice, dosing guidance or a claim of safety or effectiveness for any use in people or animals.

Get 15% Off Your First Order

Join the Zero Zero Collection list for restock alerts, new COAs and member pricing. Research use only.